ARNI (Arno Therapeutics) OCF Margin %: 0.00% (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Arno Therapeutics OCF Margin %?

Arno Therapeutics ARNI OCF Margin % is 0.00% as of Sep. 2016.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Arno Therapeutics's Cash Flow from Operations for the three months ended in Sep. 2016 was $-1.14 Mil. Arno Therapeutics's Revenue for the three months ended in Sep. 2016 was $0.00 Mil. Therefore, Arno Therapeutics's OCF Margin % for the quarter that ended in Sep. 2016 was 0.00%.

As of today, Arno Therapeutics's current OCF Yield % is -444,900.00%.

The historical rank and industry rank for Arno Therapeutics's OCF Margin % or its related term are showing as below:


ARNI's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

Arno Therapeutics OCF Margin % Related Terms

Arno Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Arno Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arno Therapeutics OCF Margin % Chart

Arno Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arno Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arno Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Arno Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2015 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2015 )/Revenue (A: Dec. 2015 )
=-9.966/0
= %

Arno Therapeutics's OCF Margin for the quarter that ended in Sep. 2016 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2016 )/Revenue (Q: Sep. 2016 )
=-1.14/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Arno Therapeutics (ARNI) has a OCF Margin % of 0.00% as of Sep. 2016. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Arno Therapeutics and its competitors.
Is Arno Therapeutics' OCF Margin % too high?
Arno Therapeutics' current OCF Margin % is 0.00%.
How does Arno Therapeutics' OCF Margin % compare to PLPL and BTHE?
Arno Therapeutics' OCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Arno Therapeutics and its competitors. Arno Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arno Therapeutics stock overvalued right now?
Arno Therapeutics (ARNI) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Arno Therapeutics (ARNI), the current OCF Margin % is 0.00% as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arno Therapeutics Business Description

Address 200 Route 31 North, Suite 104, Flemington, NJ, USA, 08822
Arno Therapeutics Inc operates as a biopharmaceutical company. It develops drug candidates to treat patients with cancer and other life-threatening diseases. It develops pre-clinical and clinical-stage product under the following name: Onapristone, AR-42, and AR-12. Onapristone is indicated for endometrial, prostate and breast cancer indications, AR-42 is provided for hematological malignancies and solid tumors indications and AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.